Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery.

Launched by FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how metabolomics, which is the analysis of small molecules in the body, can help us understand and predict how patients with metabolic syndrome might improve after surgery. Metabolic syndrome includes problems like obesity, high blood pressure, and insulin resistance, and is often linked to serious health issues like type 2 diabetes and heart disease. By examining the changes in these small molecules before and after surgery, researchers hope to identify important factors that can lead to better recovery and disease remission for patients.

To be eligible for this study, participants must be at least 18 years old and diagnosed with metabolic syndrome along with at least one related health issue, like type 2 diabetes or high blood pressure. Participants should also be planning to have surgery for their condition and need to be willing to sign a consent form and provide complete medical information. During the study, participants can expect to undergo assessments that will help researchers better understand their metabolic changes. It’s important to note that people with certain serious illnesses or those taking specific medications that could affect the study results may not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥18 years;
• • diagnosis of metabolic syndrome and combination of one or more metabolic diseases (e.g., type 2 diabetes mellitus, fatty liver disease, hypertension, etc.);
• • identification of impending related surgical treatment;
• • willingness to participate in this study and sign an informed consent form;
• • complete clinical data.
• Exclusion Criteria:
• • Patients suffering from other serious systemic diseases (e.g., severe heart disease, renal insufficiency, liver cirrhosis, etc.) or malignant tumours;
• • patients with acute diseases such as acute infections, acute myocardial infarction, acute stroke, etc.;
• • patients who are on medications that may significantly affect their metabolic status (e.g., hormonal drugs, potent immunosuppressants, etc.);
• • patients who cannot ensure compliance or are unwilling to cooperate with the study requirements;
• • patients with Serious psychological disease or cognitive dysfunction, unable to understand the content of the study or cooperate with the study operation;
• • Incomplete clinical data.